Suvoda's Groundbreaking Patent Award
In a significant leap forward for clinical trial technology, Suvoda has received a patent from the US Patent Office for its innovative software architecture, specifically regarding the Suvoda Questionnaire Definition Language (SQDL). This achievement underscores Suvoda's commitment to enhancing the efficiency of electronic Clinical Outcome Assessment (eCOA), a critical component in clinical trials.
Revolutionizing Clinical Trials with eCOA
Suvoda's eCOA solution stands out due to its low-code, no-code approach, which drastically accelerates the design and deployment of eCOA questionnaires. By simplifying questionnaire creation, localization, and licensing processes, Suvoda enables clinical trial sponsors to efficiently launch studies.
Enhancing Efficiency in Questionnaire Design
The patented architecture of Suvoda eCOA significantly reduces the time required for creating high-quality questionnaires from days to mere hours. This advancement helps to alleviate the usual bottlenecks encountered in clinical trial implementation. As noted by Jagath Wanninayake, the CEO of Suvoda, this recognition exemplifies the creativity and technical prowess of the Suvoda team in delivering robust solutions to meet clinical trial needs.
Key Advantages of Suvoda's eCOA Solution
The eCOA tool boasts several core benefits that enable sponsors to navigate the complexities of clinical trials more fluidly:
- Easy Questionnaire Creation: Suvoda eCOA empowers users without engineering backgrounds to design eCOA questionnaires effortlessly while adhering to the stringent regulatory standards.
- Parallel Processing Capabilities: By allowing simultaneous processes for questionnaire definition, licensing, and translation, the platform enhances overall efficiency. Localization partners can create and preview translations in real-time, minimizing delays.
- Smooth Mid-Study Updates: The architecture permits modifications to questionnaires mid-study without jeopardizing the validated state of the eCOA system, facilitating uninterrupted data collection.
- Component Reuse: The system enables the storage and reuse of questionnaires in a structured manner, ensuring compatibility with updates while maintaining validation.
A Comprehensive Suite of Solutions
Suvoda eCOA is part of an expansive suite of clinical trial solutions offered by the company. This comprehensive range includes Interactive Response Technology (IRT), eConsent, and the newly launched ePatient tools—all unified on the advanced Suvoda technology platform. Together, these products play a vital role in enhancing operational efficiency, reducing burdens on trial sites, and improving patient experiences during clinical trials.
About Suvoda
Founded in 2013 by experts in eClinical technologies, Suvoda has emerged as a leader in the realm of clinical trial technology, specializing in complex, life-sustaining studies across various therapeutic areas. With a dedication to empowering clinical trial professionals, Suvoda has been selected to support over 1,500 trials globally, demonstrating its effectiveness and the high regard in which it is held within the industry.
Frequently Asked Questions
What is the significance of Suvoda's recent patent?
Suvoda's patent underscores its innovative eCOA technology, which enhances the efficiency of designing and deploying clinical trial questionnaires.
How does Suvoda's eCOA differ from traditional methods?
Unlike traditional methods that often take days, Suvoda's eCOA enables questionnaire creation in hours using a low-code/no-code approach.
What benefits does the SQDL offer?
The SQDL provides ease of use for non-engineers, promotes regulatory compliance, and supports real-time feedback, improving productivity.
Can questionnaires be updated during a study?
Yes, questionnaires can be modified without affecting the validated eCOA system, ensuring ongoing data collection processes remain uninterrupted.
What types of studies does Suvoda specialize in?
Suvoda specializes in clinical trials in therapeutic areas such as oncology, central nervous system disorders, and rare diseases, offering tailored solutions to meet unique study needs.
